1.866.648.2767
    info@tabularasahealthcare.com

    Investors - Press Releases

    << Back
     View printer-friendly version
    Tabula Rasa HealthCare Announces Third Quarter 2017 Results
    Total Revenue of $33 million, up 38% year over year; Adjusted EBITDA of $4.6 million, up 43% year over year, Positive Net Income for the quarter

    MOORESTOWN, N.J., Nov. 06, 2017 (GLOBE NEWSWIRE) -- Tabula Rasa HealthCare, Inc. (“TRHC”) (NASDAQ:TRHC), a healthcare technology company optimizing medication safety by deploying new medication risk mitigation digital software solutions and novel, proprietary medication decision support tools, today announced its financial results for the third quarter ended September 30, 2017.

    “I’m extremely pleased with our performance this quarter both from a financial and operational perspective,” said Calvin H. Knowlton, PhD, TRHC’s Chairman and Chief Executive Officer. “The momentum we experienced in the first half of the year continued in the third quarter throughout all areas of our business and as a result we are increasing our revenue guidance by two million dollars for the 2017 fiscal year.”

    Dr. Knowlton continued, “Our proprietary medication risk stratification engine and medication risk score continue to get recognized as a tool for health plans to better manage medication risk for their members. By the end of the 2017 fiscal year we expect to have run 10 million patients through our engine for a variety of commercial and government sponsored health plan prospects. We plan to continue to use these tools to demonstrate the differentiated nature of our Medication Risk Mitigation platform in order to build our pipeline and, ultimately, we believe this will result in winning new customers within the health plan and PACE markets.”

    “I am also very pleased with the progress we have made toward integrating the SinfoníaRx business which we acquired on September 6th. The reaction from our existing customers has been very positive. We continue to believe that the combined company has meaningful cross-selling opportunities that we believe we will be able to capitalize on in the coming years.”

    Financial Performance for the Three Months Ended September 30, 2017

    All comparisons, unless otherwise noted, are to the three months ended September 30, 2016.

    • Total revenue was $33.3 million, an increase of 38%. Total revenue included product revenue of $24.6 million, an increase of 19%, and service revenue of $8.6 million, an increase of 151%. Product revenue increased as a result of a combination of expansion from existing clients and new clients onboarded this year. The majority of the increase in service revenue resulted from TRHC’s participation in the Enhanced Medication Therapy Management program, sponsored by the Center for Medicare and Medication Innovation, which started on January 1, 2017, as well as the contribution from the SinfoníaRx acquisition which was completed on September 6, 2017.

    • Gross margin was 29.5%, compared to 28.9%. The year over year increase is primarily related to an increase in the service revenue contribution as compared to the third quarter of 2017. Service revenue, which carries a higher gross margin, represented 26% of total revenue for the third quarter of 2017 as compared to 14% for the same period in 2016.

    • Non-GAAP Adjusted EBITDA was $4.6 million, compared to $3.3 million, an increase of 43% compared to a year ago. The increase in Adjusted EBITDA was primarily driven by growth in the business, both in the PACE market and health plan market as well as a contribution from the SinfoníaRx acquisition.

    • Adjusted EBITDA margin was 14.0% in the third quarter of 2017, up slightly from 13.5% in the same period of 2016 and was in line with management’s expectations.

    • Net income of $7.7 million compared to a net loss of $0.1 million in the third quarter of 2016. Net income was positively impacted by the partial reversal of TRHC’s deferred tax asset valuation allowance and recognition of tax windfall benefits which combined had a one-time benefit of $9.4 million in the third quarter. TRHC is no longer incurring expenses related to the restricted stock grants issued in connection with TRHC’s initial public offering.

    • Net income per diluted share was $0.41, compared to net loss per diluted share of $0.08. The net income (loss) per share calculations were based on a diluted share count of 18.6 million for the third quarter of 2017, compared to 10.3 million shares for the same period in 2016.

    • Non-GAAP Adjusted net income per diluted share was $0.08, compared to adjusted net income per diluted share of $0.04.

    • Cash at the end of the third quarter was $5.9 million compared to $4.3 million at December 31, 2016. The increase in cash was due to positive cash flow from operations, which was partially offset by a $1.5 million payment for contingent consideration made in the first quarter of 2017, $2.1 million in payments for payroll taxes remitted to taxing authorities in the second quarter of 2017 on behalf of employees from the net exercise of stock options, and $1.0 million in payments for the repurchase of common stock. TRHC also had $35.0 million drawn on its line of credit, which was used to fund the SinfoníaRx acquisition, at the end of the third quarter. 

    A reconciliation of GAAP to non-GAAP results has been provided in this press release in the accompanying tables. Non-GAAP results exclude change in fair value of warrant liability, loss on extinguishment of debt, change in fair value of acquisition-related contingent consideration expense, acquisition-related expense, payroll tax expense related to stock option exercises, stock-based compensation expense, and adjustments for the partial reversal of the deferred tax asset valuation allowance and recognition of tax windfall benefits. An explanation of these measures is also included below under the heading “Non-GAAP Financial Measures”.

    Financial Outlook

    Fourth Quarter 2017 Guidance: Revenue for TRHC’s fourth quarter 2017 is expected to be in the range of $37.5 million to $39.5 million. Net income is expected to be in the range of $1.9 million to $2.9 million. Adjusted EBITDA is expected to be in the range of $6.0 million to $7.0 million.

    Full Year 2017 Guidance: Revenue for fiscal year 2017 is now expected to be in the range of $128.0 million to $130.0 million. TRHC now expects a net income in the range of $6.5 million to $7.5 million. Net income projections include incremental stock-based compensation expense of approximately $5.2 million related to restricted stock grants issued in connection with TRHC’s initial public offering, which was fully expensed by May 2017 as well as the partial reversal of the valuation allowance and recognition of tax windfall benefits which resulted in tax benefits of $9.4 million. Adjusted EBITDA is still expected to be in the range of $17.5 million to $18.5 million.

    Quarterly Conference Call

    As previously announced, TRHC will hold a conference call with members of executive management to discuss its third quarter 2017 performance today, Monday, November 6, 2017, at 5:00 p.m. ET. Stockholders and interested participants may listen to a live broadcast of the conference call by dialing 844-413-0947 or 216-562-0423 for international callers, and referencing participant code 95876057 approximately 15 minutes prior to the call. A live webcast of the conference call will be available on the investor relations section of TRHC’s website (ir.trhc.com) and an audio file of the call will also be archived and available for replay approximately two hours after the live event for a period of 90 days thereafter at ir.trhc.com. After the conference call, a replay will be available until November 13, 2017 and can be accessed by dialing 855-859-2056 or 404-537-3406 for international callers, and referencing participant code 95876057.

    About Tabula Rasa HealthCare

    Tabula Rasa HealthCare (NASDAQ:TRHC) is a leader in providing patient-specific, data-driven technology and solutions that enable healthcare organizations to optimize medication regimens to improve patient outcomes, reduce hospitalizations, lower healthcare costs, and manage risk.  Medication risk management is TRHC’s lead offering, and its cloud-based software applications provide solutions for a range of payors, providers and other healthcare organizations. For more information, visit: www.TRHC.com.

    Non-GAAP Financial Measures

    In addition to reporting all financial information required in accordance with accounting principles generally accepted in the United States of America (“GAAP”), TRHC is also reporting Adjusted EBITDA and Adjusted Diluted EPS, each of which is a non-GAAP financial measure. Generally, a non-GAAP financial measure is a numerical measure of a company's performance or financial position that either excludes or includes amounts that are not normally excluded or included in the most directly comparable measure calculated and presented in accordance with GAAP. 

    Adjusted EBITDA consists of net income (loss) plus certain other expenses, which includes interest expense, provision (benefit) for income tax, depreciation and amortization, loss on extinguishment of debt, change in fair value of acquisition-related contingent consideration expense, change in fair value of warrant liability, acquisition-related expense, payroll tax expense related to stock option exercises and stock-based compensation expense. TRHC defines Adjusted Diluted EPS as net income (loss) attributable to common stockholders before decretion of redeemable convertible preferred stock, fair value adjustments related to the remeasurement of warrant liabilities, loss on extinguishment of debt, fair value adjustments for acquisition-related contingent consideration, acquisition-related expense, payroll tax expense related to stock option exercises, stock-based compensation expense, and the tax impact of those items as well as adjustments for tax benefits related to the partial release of our valuation allowance and recognition of tax windfall benefits expressed on a per share basis using weighted average diluted shares outstanding. TRHC believes the exclusion of these items assists in providing a more complete understanding of the company’s underlying operations results and trends and allows for comparability with TRHC’s peer company index and industry and to be more consistent with TRHC’s expected capital structure on a going forward basis. Please note that other companies might define their non-GAAP financial measures differently than TRHC does.

    TRHC presents these non-GAAP financial measures in this release because it considers them to be important supplemental measures of performance. TRHC uses these non-GAAP financial measures for planning purposes, including analysis of the company's performance against prior periods, the preparation of operating budgets and determination of appropriate levels of operating and capital investments. TRHC believes that these non-GAAP financial measures provide additional insight for analysts and investors in evaluating the company's financial and operational performance. TRHC also intends to provide these non-GAAP financial measures as part of the company's future earnings discussions and, therefore, their inclusion should provide consistency in the company's financial reporting.

    Non-GAAP financial measures have limitations as an analytical tool. Investors are encouraged to review the reconciliation of the non-GAAP measures to their most directly comparable GAAP measures provided in this release, including in the accompanying tables.

    Safe Harbor Statement

    This press release includes forward-looking statements that we believe to be reasonable as of today’s date.  Forward-looking statements give current expectation or forecasts of future events or our future financial or operating performance, and include TRHC’s expectations regarding the goals and expectations regarding the SinfoníaRx acquisition, the expected financial and operating performance of TRHC following such acquisition and expectations regarding revenues, net income and Adjusted EBITDA. Such statements are identified by use of the words “anticipates,” “believes,” “estimates,” “expects,” “intends,” “plans,” “predicts,” “projects,” “should,” and similar expressions.  These forward-looking statements are based on management's good-faith expectations, judgements and assumptions as of the date of this press release.  Actual results might differ materially from those explicit or implicit in the forward-looking statements. Important factors that could cause actual results to differ materially include: our continuing losses and need to achieve profitability; fluctuations in our financial results; the acceptance and use of our products and services by PACE organizations; the need to innovate and provide useful products and services; risks related to changing healthcare and other applicable regulations; our ability to maintain relationships with a specified drug wholesaler; increasing consolidation in the healthcare industry; managing our growth effectively; our ability to adequately protect our intellectual property; the requirements of being a public company; our ability to recognize the expected benefits from acquisitions on a timely basis or at all; our status as an “emerging growth company”; and the other risk factors set forth from time to time in our filings with the Securities and Exchange Commission (“SEC”),  including those factors discussed under the caption “Risk Factors” in our most recent annual report on Form 10-K, filed with the SEC on March 14, 2017, and in subsequent reports filed with or furnished to the SEC, copies of which are available free of charge within the Investor Relations section of the Tabula Rasa HealthCare website http://ir.trhc.com or upon request from our Investor Relations Department. Tabula Rasa HealthCare assumes no obligation and does not intend to update these forward-looking statements, except as required by law, to reflect events or circumstances occurring after today’s date.

     
    TABULA RASA HEALTHCARE, INC.
    UNAUDITED CONSOLIDATED BALANCE SHEETS
    (In thousands) 
     
        September 30,    December 31, 
        2017
      2016
    Assets    (unaudited)      
    Current assets:            
    Cash   $ 5,939     $ 4,345  
    Accounts receivable, net     16,631       6,646  
    Inventories     2,781       2,911  
    Rebates receivable     342       312  
    Prepaid expenses     2,278       869  
    Other current assets     315       581  
    Total current assets     28,286       15,664  
    Property and equipment, net     8,872       6,409  
    Software development costs, net     4,264       3,350  
    Goodwill     63,125       21,686  
    Intangible assets, net     63,347       25,297  
    Other assets     647       333  
    Total assets   $ 168,541     $ 72,739  
    Liabilities and stockholders’ equity            
    Current liabilities:            
    Current portion of long-term debt   $ 927     $ 674  
    Acquisition-related consideration payable     50       568  
    Acquisition-related contingent consideration     15,224       1,493  
    Accounts payable     14,366       6,115  
    Accrued expenses and other liabilities     8,101       2,159  
    Total current liabilities     38,668       11,009  
    Line of credit     35,000        
    Long-term debt     1,019       1,072  
    Long-term acquisition-related contingent consideration     13,652       1,515  
    Deferred income tax liability     1,592       832  
    Other long-term liabilities     2,637       2,205  
    Total liabilities     92,568       16,633  
                 
    Stockholders' equity:            
    Preferred stock            
    Common stock     2       2  
    Additional paid-in capital     108,503       91,027  
    Treasury stock     (959 )      
    Accumulated deficit     (31,573 )     (34,923 )
    Total stockholders’ equity     75,973       56,106  
    Total liabilities and stockholders’ equity   $ 168,541     $ 72,739  
                     


    TABULA RASA HEALTHCARE, INC.  
    UNAUDITED CONSOLIDATED STATEMENTS OF OPERATIONS  
    (In thousands, except share and per share amounts)  
       
        Three Months Ended   Nine Months Ended  
        September 30,    September 30,   
        2017     2016     2017     2016    
    Revenue:                          
    Product revenue   $ 24,621     $ 20,731     $ 71,391     $ 58,732    
    Service revenue     8,647       3,443       19,222       8,017    
    Total revenue     33,268       24,174       90,613       66,749    
    Cost of revenue, exclusive of depreciation and amortization shown below:                          
    Product cost     18,979       15,951       54,847       44,103    
    Service cost     4,486       1,232       9,241       3,135    
    Total cost of revenue     23,465       17,183       64,088       47,238    
    Gross profit     9,803       6,991       26,525       19,511    
    Operating expenses:                          
    Research and development     1,527       1,028       4,037       2,878    
    Sales and marketing     1,325       881       3,869       2,511    
    General and administrative     4,098       2,053       16,097       5,762    
    Change in fair value of acquisition-related contingent consideration expense     923       47       960       146    
    Depreciation and amortization     2,166       1,276       5,730       3,415    
    Total operating expenses     10,039       5,285       30,693       14,712    
    Income (loss) from operations     (236 )     1,706       (4,168 )     4,799    
    Other (income) expense:                          
    Change in fair value of warrant liability           (626 )           (639 )  
    Interest expense     174       1,242       327       4,250    
    Loss on extinguishment of debt           1,396             1,396    
    Total other expense     174       2,012       327       5,007    
    Income (loss) before income taxes     (410 )     (306 )     (4,495 )     (208 )  
    Income tax (benefit) expense     (8,105 )     (164 )     (7,845 )     11    
    Net income (loss)   $ 7,695     $ (142 )   $ 3,350     $ (219 )  
    Net income (loss) attributable to common stockholders:                          
    Basic   $ 7,695     $ 1,228     $ 3,350     $ 1,080    
    Diluted   $ 7,695     $ (803 )   $ 3,350     $ (894 )  
    Net income (loss) per share attributable to common stockholders:                          
    Basic   $ 0.46     $ 0.25     $ 0.20     $ 0.22    
    Diluted   $ 0.41     $ (0.08 )   $ 0.18     $ (0.09 )  
    Weighted average common shares outstanding:                          
    Basic     16,699,102       4,918,885       16,483,169       4,817,285    
    Diluted     18,646,031       10,333,723       18,411,800       10,232,050    
                                       


    TABULA RASA HEALTHCARE, INC.
    UNAUDITED CONSOLIDATED STATEMENTS OF CASH FLOWS
    (In thousands) 
     
        Nine Months Ended
        September 30, 
        2017     2016  
    Cash flows from operating activities:            
    Net income (loss)   $ 3,350     $ (219 )
    Adjustments to reconcile net income (loss) to net cash provided by operating activities:            
    Depreciation and amortization     5,730       3,415  
    Amortization of deferred financing costs and debt discount     72       1,255  
    Payment of imputed interest on debt           (3,893 )
    Deferred taxes     (8,137 )     (27 )
    Stock-based compensation     7,776       481  
    Change in fair value of warrant liability           (639 )
    Change in fair value of acquisition-related contingent consideration     960       146  
    Other noncash items     17        
    Loss on extinguishment of debt           1,396  
    Changes in operating assets and liabilities, net of effect from acquisition:            
    Accounts receivable, net     (1,676 )     (1,729 )
    Inventories     130       (305 )
    Rebates receivable     (30 )     759  
    Prepaid expenses and other current assets     (169 )     (114 )
    Other assets     (58 )     (171 )
    Accounts payable     29       (191 )
    Accrued expenses and other liabilities     3,274       340  
    Other long-term liabilities     432       1,973  
    Net cash provided by operating activities     11,700       2,477  
                 
    Cash flows from investing activities:            
    Purchases of property and equipment     (2,618 )     (2,947 )
    Software development costs     (2,223 )     (1,201 )
    Purchases of intangible assets           (29 )
    Change in restricted cash           200  
    Purchase of businesses, net of cash acquired     (34,452 )     (1,000 )
    Net cash used in investing activities     (39,293 )     (4,977 )
                 
    Cash flows from financing activities:            
    Payments for repurchase of common stock     (959 )      
    Proceeds from exercise of stock options     194        
    Payments for employee taxes for shares withheld     (2,123 )      
    Payments for debt financing costs     (220 )     (1,521 )
    Borrowings on line of credit     35,342       6,000  
    Repayments of line of credit     (342 )      
    Payments of acquisition-related consideration     (550 )     (180 )
    Repayment of note payable related to acquisition           (14,337 )
    Payments of initial public offering costs     (132 )     (2,191 )
    Payments of contingent consideration     (1,498 )     (1,895 )
    Proceeds from long-term debt           30,000  
    Repayments of long-term debt     (525 )     (13,609 )
    Net cash provided by financing activities     29,187       2,267  
    Net increase (decrease) in cash     1,594       (233 )
    Cash, beginning of period     4,345       2,026  
    Cash, end of period   $ 5,939     $ 1,793  
                     


    TABULA RASA HEALTHCARE, INC.
    UNAUDITED RECONCILIATION OF GAAP TO NON-GAAP MEASURES
    (In thousands except share and per share amounts)
     
        Three Months Ended September 30,    Nine Months Ended September 30, 
        2017
      2016
      2017
      2016
    Reconciliation of net income (loss) to Adjusted EBITDA                        
    Net income (loss)   $ 7,695     $ (142 )   $ 3,350     $ (219 )
    Add:                        
    Change in fair value of warrant liability           (626 )           (639 )
    Interest expense     174       1,242       327       4,250  
    Loss on extinguishment of debt           1,396             1,396  
    Income tax (benefit) expense     (8,105 )     (164 )     (7,845 )     11  
    Depreciation and amortization     2,166       1,276       5,730       3,415  
    Change in fair value of acquisition-related contingent consideration expense     923       47       960       146  
    Acquisition-related expense     855             855        
    Payroll tax expense related to stock option exercises                 95        
    Stock-based compensation expense     939       223       7,776       481  
    Adjusted EBITDA   $ 4,647     $ 3,252     $ 11,248     $ 8,841  
                                     


                                                     
        Three Months Ended September 30,    Nine Months Ended September 30, 
        2017   2016     2017   2016  
                                                                 
        (In thousands except per share amounts)   (In thousands except per share amounts)
    Reconciliation of diluted net income (loss) per share attributable to common shareholders to Adjusted Diluted EPS                                                
    Net income (loss)   $ 7,695           $ (142 )         $ 3,350           $ (219 )      
    Decretion of redeemable convertible preferred stock                 2,641                         2,439        
    Undistributed income attributable to redeemable convertible preferred stockholders                 (1,271 )                       (1,140 )      
    Net income attributable to common stockholders, basic, and net income per share attributable to common stockholders, basic   $ 7,695     $ 0.46   $ 1,228     $ 0.25     $ 3,350     $ 0.20   $ 1,080     $ 0.22  
    Decretion of redeemable convertible preferred stock                 (2,641 )                       (2,439 )      
    Revaluation of warrant liability, net of tax (1)                 (661 )                       (675 )      
    Adjustment to undistributed income attributable to redeemable convertible preferred stockholders                 1,271                         1,140        
    GAAP net income (loss) attributable to common stockholders, diluted, and net income (loss) per share attributable to common stockholders, diluted   $ 7,695     $ 0.41   $ (803 )   $ (0.08 )   $ 3,350     $ 0.18   $ (894 )   $ (0.09 )
    Adjustments:                                                
    Loss on extinguishment of debt                 1,396                         1,396        
    Change in fair value of acquisition-related contingent consideration expense     923             47             960             146        
    Acquistion-related expense     855                         855                    
    Payroll tax expense on stock option exercises                             95                    
    Stock-based compensation expense     939             223             7,776             481        
    Impact to income taxes (1)     (8,963 )           (404 )           (9,803 )           (394 )      
    Adjusted net income attributable to common stockholders and Adjusted Diluted EPS   $ 1,449     $ 0.08   $ 459     $ 0.04     $ 3,233     $ 0.18   $ 735     $ 0.06  
                                                                 

    (1) The impact to taxes was calculated using a normalized statutory tax rate applied to pre-tax income (loss) adjusted for the respective items above and then subtracting the tax provision as determined for GAAP purposes.

                     
        Three Months Ended   Nine Months Ended
        September 30,    September 30, 
        2017   2016   2017   2016
    Reconciliation of weighted average shares of common stock outstanding, diluted, to weighted average shares of common stock outstanding, diluted for Adjusted Diluted EPS                
    Weighted average shares of common stock outstanding   16,699,102   4,918,885   16,483,169   4,817,285
    Effect of potential dilutive securities:                
    Weighted average dilutive effect of stock options   1,235,883     1,308,202  
    Weighted average dilutive effect of restricted shares   711,046     607,988  
    Weighted average dilutive effect of common shares from warrants       12,441  
    Dilutive effect from preferred stock and preferred stock warrants assuming conversion at beginning of the year     5,414,838     5,414,765
    Weighted average shares of common stock outstanding, basic and diluted for GAAP   18,646,031   10,333,723   18,411,800   10,232,050
    Adjustments:                
    Weighted average dilutive effect of stock options     1,994,389     1,983,298
    Weighted average dilutive effect of common shares from stock warrants     203,486     266,501
    Weighted average dilutive effect of restricted stock     3,221     1,081
    Weighted average shares of common stock outstanding, diluted for Adjusted Diluted EPS   18,646,031   12,534,819   18,411,800   12,482,930
                     


    TABULA RASA HEALTHCARE, INC.
    UNAUDITED RECONCILIATION OF GAAP TO NON-GAAP GUIDANCE RANGES
    (In millions)
     
        LOW   HIGH   LOW   HIGH
        Three Months Ended December 31, 2017   Year Ended December 31, 2017
    Reconciliation of Adjusted EBITDA to net income                        
    Net income   $ 1.9     $ 2.9     $ 6.5     $ 7.5  
    Add:                        
    Interest expense     0.5       0.5       0.8       0.8  
    Income tax benefit     (0.8 )     (0.8 )     (8.6 )     (8.6 )
    Depreciation and amortization     3.4       3.4       9.1       9.1  
    Stock-based compensation expense     1.0       1.0       8.8       8.8  
    Transaction based costs                 0.9       0.9  
    Adjusted EBITDA   $ 6.0     $ 7.0     $ 17.5     $ 18.5  
                                     

    Contact:

    Investors
    Bob East or Asher Dewhurst
    Westwicke Partners
    443-213-0500
    tabularasa@westwicke.com 

    Media
    Dianne Semingson
    dsemingson@TRHC.com 
    T: 215-870-0829

    Tabula Rasa HealthCare, Inc.